HK1154505A1 - Process to minimize polymorphism - Google Patents
Process to minimize polymorphismInfo
- Publication number
- HK1154505A1 HK1154505A1 HK11108783.1A HK11108783A HK1154505A1 HK 1154505 A1 HK1154505 A1 HK 1154505A1 HK 11108783 A HK11108783 A HK 11108783A HK 1154505 A1 HK1154505 A1 HK 1154505A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- polymorphism
- minimize
- minimize polymorphism
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3229808P | 2008-02-28 | 2008-02-28 | |
PCT/US2009/035276 WO2009108775A2 (en) | 2008-02-28 | 2009-02-26 | Process to minimize polymorphism |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1154505A1 true HK1154505A1 (en) | 2012-04-27 |
Family
ID=41016708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11108783.1A HK1154505A1 (en) | 2008-02-28 | 2011-08-19 | Process to minimize polymorphism |
Country Status (19)
Country | Link |
---|---|
US (1) | US20090226522A1 (ja) |
EP (1) | EP2247284B1 (ja) |
JP (2) | JP5547096B2 (ja) |
KR (1) | KR101473419B1 (ja) |
CN (2) | CN103751091B (ja) |
AR (1) | AR072245A1 (ja) |
AU (1) | AU2009219292B2 (ja) |
BR (1) | BRPI0908539B8 (ja) |
CA (1) | CA2716901C (ja) |
DK (1) | DK2247284T3 (ja) |
ES (1) | ES2633928T3 (ja) |
HK (1) | HK1154505A1 (ja) |
IL (2) | IL207824A (ja) |
MX (1) | MX2010009493A (ja) |
MY (1) | MY173867A (ja) |
NZ (1) | NZ587611A (ja) |
RU (1) | RU2010139643A (ja) |
WO (1) | WO2009108775A2 (ja) |
ZA (1) | ZA201006421B (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013009255B1 (pt) * | 2010-10-08 | 2021-02-23 | R.P. Scherer Technologies, Llc | composição sólida de vacina oral de dissolução rápida |
US10603272B2 (en) | 2015-02-27 | 2020-03-31 | Kindred Biosciences, Inc. | Stimulation of appetite and treatment of anorexia in dogs and cats |
CN107951893B (zh) * | 2016-10-18 | 2022-04-26 | 天津金耀集团有限公司 | 一种糠酸莫米松粉吸入剂组合物 |
CN110337290A (zh) | 2016-12-31 | 2019-10-15 | 比奥克斯塞尔医疗股份有限公司 | 舌下右旋美托咪啶用于治疗激越的用途 |
JP7488201B2 (ja) | 2018-06-27 | 2024-05-21 | バイオエクセル セラピューティクス,インコーポレイテッド | デクスメデトミジンを含むフィルム製剤、及びその作製方法 |
CN109010295A (zh) * | 2018-08-29 | 2018-12-18 | 北京兴源联合医药科技有限公司 | 一种左甲状腺素钠冻干口腔崩解片 |
CN109316452B (zh) * | 2018-09-07 | 2021-07-30 | 北京兴源联合医药科技有限公司 | 一种硫酸氢氯吡格雷冻干口腔崩解片 |
HUE064472T2 (hu) | 2019-02-22 | 2024-03-28 | Catalent Uk Swindon Zydis Ltd | Agglomeráció, aeráció minimalizálása, és ibuprofent tartalmazó gyógyszerészeti készítmények bevonatának védelme |
KR20210130722A (ko) | 2019-02-22 | 2021-11-01 | 카탈렌트 유.케이. 스윈던 지디스 리미티드 | 의약품의 붕해 시간을 안정화하기 위한 저장 동안 약물 입자 코팅 물질의 응집 최소화 |
CA3145388A1 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
EP4188324A1 (en) * | 2020-07-31 | 2023-06-07 | Catalent U.K. Swindon Zydis Limited | Pharmaceutical compositions comprising coated api |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4946684A (en) * | 1989-06-20 | 1990-08-07 | American Home Products Corporation | Fast dissolving dosage forms |
DD289468B5 (de) | 1989-11-07 | 1994-02-10 | Dresden Arzneimittel | Arzneimitteltechnologisches verfahren zur herstellung einer alprazolam-arzneiform |
CA2020018A1 (en) * | 1990-06-27 | 1991-12-28 | Don L. Simmons | Method and composition for treating the migraine complex |
DE69331839T2 (de) * | 1992-01-29 | 2002-12-12 | Takeda Chemical Industries, Ltd. | Schnellösliche Tablette und ihre Herstellung |
AU691195B2 (en) * | 1993-07-09 | 1998-05-14 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
US5457895A (en) * | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
CZ289649B6 (cs) * | 1994-07-22 | 2002-03-13 | Krka, Tovarna Zdravil. P.O. | Pevné lékové formy se spolehlivým uvolňováním aktivní sloľky alprazolamu a způsob jejich přípravy |
DK0893992T3 (da) * | 1996-04-16 | 2004-06-01 | Novartis Consumer Health Sa | Hurtigt sönderdelende oral doseringsform |
US5958453A (en) * | 1996-10-31 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
US6010719A (en) * | 1997-09-16 | 2000-01-04 | Universiteit Gent | Freeze-dried disintegrating tablets |
ATE285449T1 (de) * | 1997-12-26 | 2005-01-15 | Warner Lambert Co | Gelatinzusammensetzungen |
GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
US6509040B1 (en) * | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
EP1401503B1 (en) | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
US7972621B2 (en) * | 2004-06-03 | 2011-07-05 | R.P. Scherer Technologies, Llc | Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight |
US7855196B2 (en) * | 2005-08-22 | 2010-12-21 | Pierre Mainville | Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist |
CA2626551A1 (en) * | 2005-11-09 | 2007-08-02 | Dow Pharmaceutical Sciences | Azithromycin for treatment of granulomatous rosacea |
GB0714223D0 (en) * | 2007-07-20 | 2007-08-29 | Fujifilm Mfg Europe Bv | Preparation of fine particles |
-
2009
- 2009-02-26 MX MX2010009493A patent/MX2010009493A/es active IP Right Grant
- 2009-02-26 BR BRPI0908539A patent/BRPI0908539B8/pt active IP Right Grant
- 2009-02-26 CN CN201310484741.7A patent/CN103751091B/zh active Active
- 2009-02-26 US US12/393,584 patent/US20090226522A1/en not_active Abandoned
- 2009-02-26 CN CN2009801157337A patent/CN102036655B/zh active Active
- 2009-02-26 MY MYPI2010004071A patent/MY173867A/en unknown
- 2009-02-26 WO PCT/US2009/035276 patent/WO2009108775A2/en active Application Filing
- 2009-02-26 CA CA2716901A patent/CA2716901C/en active Active
- 2009-02-26 AU AU2009219292A patent/AU2009219292B2/en not_active Ceased
- 2009-02-26 EP EP09713721.0A patent/EP2247284B1/en active Active
- 2009-02-26 RU RU2010139643/15A patent/RU2010139643A/ru not_active Application Discontinuation
- 2009-02-26 NZ NZ587611A patent/NZ587611A/en not_active IP Right Cessation
- 2009-02-26 KR KR1020107021356A patent/KR101473419B1/ko active IP Right Grant
- 2009-02-26 JP JP2010548864A patent/JP5547096B2/ja active Active
- 2009-02-26 DK DK09713721.0T patent/DK2247284T3/en active
- 2009-02-26 ES ES09713721.0T patent/ES2633928T3/es active Active
- 2009-02-27 AR ARP090100677A patent/AR072245A1/es not_active Application Discontinuation
-
2010
- 2010-08-26 IL IL207824A patent/IL207824A/en active IP Right Grant
- 2010-09-07 ZA ZA2010/06421A patent/ZA201006421B/en unknown
-
2011
- 2011-08-19 HK HK11108783.1A patent/HK1154505A1/xx not_active IP Right Cessation
-
2013
- 2013-12-11 JP JP2013256105A patent/JP2014062119A/ja active Pending
-
2017
- 2017-06-06 IL IL252713A patent/IL252713A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN102036655A (zh) | 2011-04-27 |
CA2716901C (en) | 2018-07-03 |
NZ587611A (en) | 2012-07-27 |
KR101473419B1 (ko) | 2014-12-16 |
EP2247284B1 (en) | 2017-04-19 |
JP2014062119A (ja) | 2014-04-10 |
BRPI0908539B8 (pt) | 2021-05-25 |
WO2009108775A3 (en) | 2009-12-03 |
CN103751091B (zh) | 2017-08-25 |
IL252713A0 (en) | 2017-08-31 |
JP2011513324A (ja) | 2011-04-28 |
ZA201006421B (en) | 2011-05-25 |
BRPI0908539B1 (pt) | 2020-12-08 |
EP2247284A4 (en) | 2013-10-02 |
AR072245A1 (es) | 2010-08-18 |
AU2009219292A1 (en) | 2009-09-03 |
CA2716901A1 (en) | 2009-09-03 |
WO2009108775A2 (en) | 2009-09-03 |
KR20100123740A (ko) | 2010-11-24 |
AU2009219292B2 (en) | 2014-02-27 |
IL207824A (en) | 2017-11-30 |
DK2247284T3 (en) | 2017-07-31 |
CN103751091A (zh) | 2014-04-30 |
US20090226522A1 (en) | 2009-09-10 |
MX2010009493A (es) | 2010-12-20 |
EP2247284A2 (en) | 2010-11-10 |
ES2633928T3 (es) | 2017-09-26 |
RU2010139643A (ru) | 2012-04-10 |
IL207824A0 (en) | 2010-12-30 |
JP5547096B2 (ja) | 2014-07-09 |
CN102036655B (zh) | 2013-11-20 |
MY173867A (en) | 2020-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL252713A0 (en) | A process for reducing multiforms | |
GB0806422D0 (en) | Process | |
GB0806419D0 (en) | Process | |
GB0808836D0 (en) | Process | |
GB0814519D0 (en) | Process | |
GB0812742D0 (en) | Process | |
GB0814053D0 (en) | Process | |
GB0801209D0 (en) | Process | |
GB0803669D0 (en) | Process | |
GB0801580D0 (en) | Process | |
GB0813598D0 (en) | Process | |
GB0813433D0 (en) | Process | |
GB0800875D0 (en) | Process | |
GB0812400D0 (en) | Process | |
GB0811851D0 (en) | Process | |
GB0807161D0 (en) | Process | |
GB0803960D0 (en) | Process | |
GB0808764D0 (en) | Process | |
GB0808357D0 (en) | Process | |
GB0812919D0 (en) | Process | |
GB0803663D0 (en) | Process | |
GB0812098D0 (en) | Process | |
GB0808359D0 (en) | Process | |
GB0815882D0 (en) | Novel process | |
GB0822880D0 (en) | Novel process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20240223 |